ClinicalTrials.gg
TerminatedNCT03250767Updated Nov 9, 2023

Clinical Evaluation of the Integra® Titan™ Modular Shoulder System Generation 2.5 for Primary Shoulder Joint Replacement

An observational study in Osteo Arthritis Shoulders, Traumatic Arthritis and Rheumatoid Arthritis, sponsored by Smith & Nephew, Inc.. Terminated at 7 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-11-09.

Sponsored by Smith & Nephew, Inc. · Observational

How we know

Why this study was terminated
Sponsor decision not due to adverse events, complications, or device issues.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
58
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 13 studies in Arthritis, Rheumatoid by Smith & Nephew, Inc. — none open to participants now, 1 under way, none of them phase 3. Arthritis, Rheumatoid · Smith & Nephew, Inc..

Started
2017
with 3 others
Observational
8 of 13
none open now
Registered
11th of 13
by date

Among the 13 studies in Arthritis, Rheumatoid by Smith & Nephew, Inc., this one is one of 4 that started in 2017, is one of 8 observational ones, and was the 11th registered.

Arthritis, Rheumatoid

3,338 studies on the registry are indexed under Arthritis, Rheumatoid; 446 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

None of the 13 studies in Arthritis, Rheumatoid by Smith & Nephew, Inc. is open now. The open studies under Arthritis, Rheumatoid, anywhere →

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 13 studies in Arthritis, Rheumatoid by Smith & Nephew, Inc. as a file.
02

Study summary

A post market, prospective, non-randomized, multi-center, open-label, clinical study using survivorship as the reference performance goal to study the safety and efficacy of the Titan Modular Shoulder System 2.5 when used for primary shoulder arthroplasty.

03

Conditions studied

  • Osteo Arthritis Shoulders
  • Traumatic Arthritis
  • Rheumatoid Arthritis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with shoulder arthritis requiring primary shoulder joint replacement

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • For total shoulder arthroplasty, subjects must meet a, b, or c below:

    1. Severely painful and/or disabled joint resulting from osteoarthritis, traumatic arthritis or rheumatoid arthritis
    2. Fracture-dislocations of the proximal humerus where the articular surface is severely comminuted, separated from its blood supply or where the surgeon's experience indicates that alternative methods of treatment are unsatisfactory
    3. Other difficult clinical problems where shoulder arthrodesis or resection arthroplasty are not acceptable (e.g. -revision of a failed primary component)
  • For shoulder hemiarthroplasty, subjects must meet any of the sub-criteria a - g below:

    1. Severely painful and/or disabled joint resulting from osteoarthritis, traumatic arthritis or rheumatoid arthritis
    2. Fracture-dislocations of the proximal humerus where the articular surface is severely comminuted, separated from its blood supply or where the surgeon's experience indicates that alternative methods of treatment are unsatisfactory
    3. Other difficult clinical problems where shoulder arthrodesis or resection arthroplasty are not acceptable (e.g. -revision of a failed primary component)
    4. Ununited humeral head fractures
    5. Avascular necrosis of the humeral head
    6. Rotator cuff arthropathy
    7. Deformity and/or limited motion

Exclusion criteria

Exclusion Criteria:

  • Absent, irreparable or nonfunctional rotator cuff or other essential muscles.
  • Have an active local or systemic infection.
  • Have inadequate bone stock in the proximal humerus or glenoid fossa for supporting the components.
  • Have poor bone quality such as osteoporosis where there could be considerable migration of the prosthesis and/or a chance of fracture of the humerus or glenoid.
  • Have a muscular, neurologic, or vascular deficiencies that compromise the affected extremity.
  • Have a known sensitivity or allergic reaction to one or more of the implanted materials.
  • Have a condition that may impair proper wound healing.
05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
58 participants (actual)
Patient registry
No

Groups and cohorts

  • Integra Titan Modular Shoulder System 2.5

    Device: Integra Titan Modular Shoulder System 2.5

Interventions

  • DeviceIntegra Titan Modular Shoulder System 2.5

    Primary Shoulder Joint Replacement

06

What researchers measure

Primary outcomes

  1. Implant Survivorship

    Implant survivorship defined as absence of device removal or revision

    Time frame: 2 years

Secondary outcomes

  1. Implant Survivorship

    Implant survivorship defined as absence of device removal or revision

    Time frame: 1,5 and 10 years

  2. Relative change of Range of Motion (ROM) compared to baseline

    Relative change of ROM compared to baseline

    Time frame: up to 10 years

  3. Relative change of Constant-Murley Score (CMS) compared to baseline

    Relative change of CMS compared to baseline

    Time frame: up to 10 years

  4. Relative change of American Shoulder & Elbow Surgeons Score (ASES) compared to baseline

    Relative change of ASES compared to baseline

    Time frame: up to 10 years

  5. Relative change of Single Assessment Numeric Evaluation (SANE) compared to baseline

    Relative change of SANE compared to baseline

    Time frame: up to 10 years

  6. Relative change of Simple Shoulder Test (SST) compared to baseline

    Relative change of SST compared to baseline

    Time frame: up to 10 years

  7. Relative change of Pain compared to baseline

    Relative change of Visual Analogue Scale (VAS) Pain compared to baseline

    Time frame: up to 10 years

07

Study locations

7 sites
  • University of Alabama at Birmingham
    Birmingham, Alabama 35294-0111, United States
  • John Hopkins University
    Columbia, Maryland 21044, United States
  • Mississipi Bone and Joint Clinic
    Starkville, Mississippi 39759, United States
  • The Research Foundation for The State University of New York (SUNY)
    Syracuse, New York 13210, United States
  • Westphal Orthopaedics
    Lancaster, Pennsylvania 17601, United States
  • Hospital of the University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
  • The Rothman Institute
    Philadelphia, Pennsylvania 19107, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2017 to primary completion in Mar 2023, 67 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 11, 2017
First posted
Aug 16, 2017
StartActual
Aug 1, 2017
Primary completionActual
Mar 10, 2023
CompletionActual
Mar 10, 2023
Last update
Nov 9, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 9, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03250767
Responsible party
Sponsor
First posted
Aug 16, 2017
Start date
Aug 1, 2017
Primary completion
Mar 10, 2023
Completion
Mar 10, 2023
Last update
Nov 9, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion